Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Comparison of two immunoassay systems for hCGβ and PAPP-A in prenatal screening for trisomy 21, 18, and 13 in the first trimester

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Reliability of Pain Measurements Using Computerized Cuff Algometry: A DoloCuff Reliability and Agreement Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objectives: Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1-2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration.

Design and methods: Fifty-five stool samples were analyzed by the IBDoc® Calprotectin Home Testing kit and the BÜHLMANN fCAL® turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated.

Results: We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL® turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3-5.5% (BÜHLMANN fCAL® turbo) and in the range of 4.8-26.6% (IBDoc®).

Conclusions: This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients.

Original languageEnglish
JournalPractical Laboratory Medicine
Volume10
Pages (from-to)10-14
ISSN2352-5517
DOIs
Publication statusPublished - Mar 2018

    Research areas

  • Journal Article

ID: 52170403